← All trials
NCT05930457
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 26, 2023
- Primary completion
- Oct 31, 2023
- Completion date
- Dec 18, 2023
- First posted
- Jul 5, 2023
- Last posted
- Dec 26, 2023
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Guangzhou Medical UniversityLead sponsor
- Guangzhou Medical UniversityReponsible party - principal investigator
- Sinotau Pharmaceutical GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.